Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Heresco-Levy

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Schizophrenia Bulletin|September 9, 1999
Treatment-resistant schizophrenia and staff rejectionU Heresco-Levy, M Ermilov, B Giltsinsky, et al.
The Israel Journal of Psychiatry and Related Sciences|January 1, 1995
Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapseU Heresco-Levy, D Greenberg, B Lerer, et al.
The Journal of Clinical Psychiatry|February 1, 1993
Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcomeU Heresco-Levy, D Greenberg, B Lerer, et al.
The Israel Journal of Psychiatry and Related Sciences|January 1, 1997
Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapyU Heresco-Levy, D Greenberg, B Lerer, et al.
The British Journal of Psychiatry : the Journal of Mental Science|November 1, 1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophreniaU Heresco-Levy, D C Javitt, M Ermilov, et al.
Archives of General Psychiatry|January 19, 1999
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophreniaU Heresco-Levy, D C Javitt, M Ermilov, et al.
The American Journal of Psychiatry|August 1, 1994
Amelioration of negative symptoms in schizophrenia by glycineD C Javitt, I Zylberman, S R Zukin, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 1, 1997
Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjectsY Kohn, R P Ebstein, U Heresco-Levy, et al.
Psychiatric Genetics|July 1, 1997
Schizophrenia, chronic hospitalization and the 5-HT2C receptor geneR H Segman, R P Ebstein, U Heresco-Levy, et al.
Molecular Psychiatry|April 20, 1999
Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophreniaO Agid, B Shapira, J Zislin, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Schizophrenia Bulletin|September 9, 1999
Treatment-resistant schizophrenia and staff rejectionU Heresco-Levy, M Ermilov, B Giltsinsky, et al.
The Israel Journal of Psychiatry and Related Sciences|January 1, 1995
Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapseU Heresco-Levy, D Greenberg, B Lerer, et al.
The Journal of Clinical Psychiatry|February 1, 1993
Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcomeU Heresco-Levy, D Greenberg, B Lerer, et al.
The Israel Journal of Psychiatry and Related Sciences|January 1, 1997
Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapyU Heresco-Levy, D Greenberg, B Lerer, et al.
The British Journal of Psychiatry : the Journal of Mental Science|November 1, 1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophreniaU Heresco-Levy, D C Javitt, M Ermilov, et al.
Archives of General Psychiatry|January 19, 1999
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophreniaU Heresco-Levy, D C Javitt, M Ermilov, et al.
The American Journal of Psychiatry|August 1, 1994
Amelioration of negative symptoms in schizophrenia by glycineD C Javitt, I Zylberman, S R Zukin, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 1, 1997
Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjectsY Kohn, R P Ebstein, U Heresco-Levy, et al.
Psychiatric Genetics|July 1, 1997
Schizophrenia, chronic hospitalization and the 5-HT2C receptor geneR H Segman, R P Ebstein, U Heresco-Levy, et al.
Molecular Psychiatry|April 20, 1999
Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophreniaO Agid, B Shapira, J Zislin, et al.
Pageof 3